Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02305134
Other study ID # G26023
Secondary ID UMIN000015748
Status Completed
Phase Phase 1/Phase 2
First received
Last updated
Start date June 11, 2015
Est. completion date March 2019

Study information

Verified date March 2019
Source Chiba University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Tipepidine (3-[di-2-thienylmethylene]-1-methylpiperidine) has been used solely as a nonnarcotic antitussive in Japan since 1959. The safety of tipepidine in children and adults has already been established. It is reported that tipepidine inhibits G-protein-coupled inwardly rectifying potassium (GIRK)-channel currents. The inhibition of GIRK channels by tipepidine is expected to modulate the level of monoamines in the brain. We put forward the hypothesis that tipepidine can improve attention deficit/hyperactivity disorder (ADHD) symptoms by modulating monoaminergic neurotransmission through the inhibition of GIRK channels. The purpose of this double-blind, placebo-controlled trial is to confirm whether treatment with tipepidine can improve symptoms in pediatric patients with ADHD.


Description:

Tipepidine (3-[di-2-thienylmethylene]-1-methylpiperidine) has been used solely as a nonnarcotic antitussive in Japan since 1959. The safety of tipepidine in children and adults has already been established. It is reported that tipepidine inhibits G-protein-coupled inwardly rectifying potassium (GIRK)-channel currents. The inhibition of GIRK channels by tipepidine is expected to modulate the level of monoamines in the brain. We put forward the hypothesis that tipepidine can improve attention deficit/hyperactivity disorder (ADHD) symptoms by modulating monoaminergic neurotransmission through the inhibition of GIRK channels. The purpose of this double-blind, placebo-controlled trial is to confirm whether treatment with tipepidine can improve symptoms in pediatric patients with ADHD.

See our previous open trial, An Open Study of Tipepidine Hibenzate in Patients With Attention Deficit Hyperactivity Disorder (ADHD) http://clinicaltrials.gov/show/NCT01835093


Recruitment information / eligibility

Status Completed
Enrollment 21
Est. completion date March 2019
Est. primary completion date March 2019
Accepts healthy volunteers No
Gender All
Age group 6 Years to 17 Years
Eligibility [Inclusion Criteria]

1. Diagnosis of attention deficit hyperactivity disorder besed on DSM-5 criteria.

2. Scores of 20 or higher in ADHD-RS (physician evaluation) total score.

3. currently is an outpatient at Chiba University Hospital Department of Psychiatry or Child Psychiatry.

4. currently receiving no medications for ADHD (atomoxetine, methylphenidate) treatment for the previous 4 weeks prior to enrollment in this study.

5. currently receiving no medications of antidepressants, mood stabilizers and the antipsychotics treatment for the previous 4 weeks prior to enrollment in this study.

6. currently receiving no medications of GIRK channel antagonist (tipepidine, cloperastine, caramiphen) treatment for the previous 4 weeks prior to enrollment in this study.

7. Ages 6 - 17, male or female

8. Provision of written informed consent by patients and parents or guardian.

9. must be able to swallow capsuled medicine.

[Exclusion Criteria]

1. History of allergic reaction or hypersensitivity to tipepidine hibenzate.

2. Patients who have not been informed of having the disease at the time of informed consent.

3. Diagnosis of any of the following diseases based on the DSM-5 criteria. Autism Spectrum Disorder, Schizophrenia Spectrum and Other Psychotic Disorders, Neurocognitive Disorders, Substance Related and Addictive Disorders, Feeding and Eating Disorders, Personality Disorders, Paraphilic Disorders.

4. currently receiving medications for ADHD (atomoxetine, methylphenidate) treatment for the previous 4 weeks prior to enrollment in this study.

5. currently receiving medications of antidepressants, mood stabilizers and the antipsychotics treatment for the previous 4 weeks prior to enrollment in this study.

6. currently receiving medications of GIRK channel antagonist (tipepidine, cloperastine, caramiphen) treatment for the previous 4 weeks prior to enrollment in this study.

7. Somatic disorder which requires severe body management or severe meal management.

8. participating in another clinical trial within 3 months prior to enrollment into this study. (except for observation study without intervention).

9. planning change of treatment because of unstable neurological manifestations or somatic symptoms.

10. History of suicidal ideation within the past year.

11. pregnant or nursing, or intending to become pregnant or to start breastfeeding during the study.

12. Other clinically significant reasons for exclusion by investigators.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tipepidine Hibenzate

Placebo


Locations

Country Name City State
Japan Department of Psychiatry, Chiba University School of Medicine Chiba Chuo-ku

Sponsors (1)

Lead Sponsor Collaborator
Chiba University

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary The ADHD Rating Scale IV Japanese Version (ADHD-RS-IV-J) by physician. The ADHD Rating Scale-IV obtains parent ratings regarding the frequency of each ADHD symptom based on DSM-IV criteria. The ADHD Rating Scale-IV is completed independently by the parent and scored by a clinician. The scale consists of 2 subscales: inattention (9 items) and hyperactivity-impulsivity (9 items). Changes from baseline in ADHD-RS-IV-J at 4-weeks
Secondary Subscores (Inattentive subscore, Hyperactive/impulsive subscore) of the ADHD-RS-IV-J by physician. Changes from baseline in at 4-weeks
Secondary Total scores and subscores (Inattentive subscore, Hyperactive/impulsive subscore) of the ADHD-RS-IV-J by parents. Changes from baseline in at 4-weeks
Secondary Total scores and subscores (planning subscore, attention subscore, simultaneous subscore, successive subscore) of DN-CAS (Das-Naglieri Cognitive Assessment System) Japanese Version. The DN-CAS is an assessment battery designed to evaluate cognitive processing. It was developed to integrate theoretical and applied areas of psychological knowledge using cognitive processing theory and tests designed to measure—Planning, Attention, Simultaneous, and Successive Processing (PASS)—in individuals ages 5-17. This assessment facilitates mental health professionals in the identification of Attention-Deficit/Hyperactivity Disorder, Traumatic Brain Injury, learning disabilities, Mental Retardation, and giftedness. Changes from baseline in at 4-weeks
Secondary Scores of CGI-ADHD-S, CGI-ADHD-I Changes from baseline in at 4-weeks
Secondary Biologocal markers (Serum levels of Pro-BDNF, Mature-BDNF, Oxytocin) Changes from baseline in at 4-weeks
See also
  Status Clinical Trial Phase
Completed NCT00600470 - Effectiveness of Collaborative Services in Primary Care for Treating Children With Behavior Disorders Phase 1/Phase 2
Completed NCT03698240 - Mindfulness-based Program for Children With Disruptive Behavior Disorder N/A
Completed NCT02766101 - Manville Moves: an Exercise Intervention for Behavioral Regulation Among Children With Behavioral Health Challenges N/A
Completed NCT02897570 - Metabolic and Neurofunctional Responses to Breakfasts N/A
Recruiting NCT04946253 - SKIP for PA Study: Team and Leadership Level Implementation Support for Collaborative Care N/A
Completed NCT00402857 - Parent Training to Promote Early Identification and Treatment of Childhood Behavioral Disorders Phase 3
Completed NCT03597789 - Tantrum Tamers 2.0: The Role of Emotion N/A
Recruiting NCT01350986 - Guided Self-Help for Parents of Children With Externalizing Problem Behavior N/A
Completed NCT00163865 - A Pilot Study of Boredom in a Community Sample of Adolescents and a Clinical Sample of Adolescents N/A
Completed NCT02893852 - Effects of CO-OP Approach on Activity and Participation of Brazilian Children With Developmental Coordination Disorder N/A
Terminated NCT02094612 - Effectiveness of the Quotient® ADHD Assessment in a System of Care N/A
Completed NCT01940978 - A Study of Combination Therapy in Children With ADHD Phase 4
Completed NCT03927612 - Virtual Reality to Improve Social Perspective Taking N/A
Completed NCT03976570 - The Effect of Occupational Therapy on Subthreshold Attention Deficit Hyperactivity Disorder N/A
Recruiting NCT04238403 - Peer Professionals to Increase Capacity to Treat ADHD N/A
Completed NCT00218114 - Divalproex Sodium (Depakote) for Explosive Tempers in Adolescents and Adults Phase 3
Completed NCT01919073 - Efficacy of a Brief Behavioral Intervention to Treat ADHD and Disruptive Behaviors In Preschoolers N/A
Completed NCT00236444 - A Study of the Efficacy and Safety of Risperidone in the Prevention of Relapse in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders Phase 3
Completed NCT00001233 - Study of Children at Risk for Disruptive Behavior Disorders N/A
Recruiting NCT05683756 - A Sleep Focused Parenting Intervention for Preschool Aged Children at Risk for ADHD N/A